Under the Papersonk Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number STATEMENT UNDER 37 CFR 3,73(c) Applicant/Patent Owner: EVOLVA SA Application No./Patent No.: 7,018,829 Filed/Issue Date: 03/28/2006 Tillad Metabolically Engineered Microbial Cell with an Altered Metabolite Production a Corporation EVOLVA SA (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.) states that, for the patent application/patent identified above, it is (choose one of options 1, 2, 3 or 4 below): The assignee of the entire right, title, and interest. An assignee of less than the entire right, title, and interest (check applicable box): The extent (by percentage) of its ownership interest is __ %. Additional Statement(s) by the owners holding the balance of the interest must be submitted to account for 100% of the ownership interest. There are unspecified percentages of ownership. The other parties, including inventors, who together own the entire right, title and interest are: Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest, 3. The assignee of an undivided interest in the entirety (a complete assignment from one of the joint inventors was made). The other parties, including inventors, who together own the entire right, title, and interest are: Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest, The recipient, via a court proceeding or the like (e.g., bankn.ptcv, probate), of an undivided interest in the entirety (a. complete transfer of ownership interest was made). The certified document(s) showing the transfer is attached. The interest identified in option 1, 2 or 3 above (not option 4) is evidenced by either (choose one of options A or B below); A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel Frame , or for which a copy thereof is attached. B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: 1. From: Jens Nielsen, et al. To: N&N Biotech APS The document was recorded in the United States Patent and Trademark Office at Reel 013507 Frame 0556 or for which a copy thereof is attached. 2. From: N&N Biotech APS To: Fluxome Sciences APS

[Page 1 of 2]

, or for which a copy thereof is attached.

This collection of information is required by 37 CFR 3.73(b). The information is designed in obtain or retain a benefit by the public which is to file (and by the USFTOLD process) an application. Confidentiality is governed by 35 LSR 0.73(c) and 37 CFR 1.11 and 1.14. The collection is destinated in their in many process in application. Confidentiality is governed by 35 LSR 0.73 care of the USFTOLD time will very depending upon the individual case. Any comments on the amount of time your requires to complete the size formation and or suppositions for reducing this individual, should be served to the CMF information Officer. US Patient and Trademark.

Officer US. Department of Commerce. P.O. Bos. 1450, Alexandria, VA. 22:161-169. DE VIDT SEND FEES OR COMPLETED PORUS TO THIS ADDRESS. SEND.

TO: Commissioner for Patients, P.O. Bos. 1450, Alexandria, VA. 22:161-169. DE VIDT SEND FEES OR COMPLETED PORUS TO THIS ADDRESS. SEND.

The document was recorded in the United States Patent and Trademark Office at

Frame 0342

PTOMARGE 68-13.

Approved for use through 0.12/102/5 MB 685-0031

Use the Paperwish Reduction Act of 1995, no pergoing are inquired to regional to regulator of information unless of displays a valid Continuation unless of displays and displays a valid Continuation unless of displays and displays a valid Continuation unless of displays a valid Continuation unless of displays and displays a valid continuation unless of displays a valid continua

		STATEMEN	T UNDER 37 CFR 3.73	(c)
3. From	Fluxome Sciences APS		To: Fluxome Science	es AS
			Ated States Patent and Trade	
4. From	Fluxome Sciences AS		To: Evolva SA	***************************************
	The document wa	s recorded in the Un	ofted States Patent and Trade	mark Office at
5. From	C		То:	
The document was recorded in the United States Patent and Trademark Office at				
	Reel	Frame	, or for which a copy the	ereof is attached.
6. From			То:	
The document was recorded in the United States Patent and Trademark Office				mark Office at
	Reel	, Frame		ereof is attached.
	Additional documents in th	e chain of title are li	isted on a supplemental shee	t(s).
7			entary evidence of the chain of do recordation pursuant to	if title from the original owner to the 37 CFR 3.11.
				nt(s)) must be submitted to Assignment cords of the USPTO. See MPEP 302.08]
The un	deraigned (whose title is supp	olied below) is autho	rized to act on behalf of the a	
/Stev	en J. Sarussi/			February 12, 2013
Signature				Date
Steven J. Sarussi				32,784
Printed or Typed Name				Title or Registration Number

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuent to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a confractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the international Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another tederal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. À record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.